A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults

Trial Profile

A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents With Hypertension and Healthy Adults

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2016

At a glance

  • Drugs Azilsartan medoxomil (Primary)
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors Takeda; Takeda Global Research and Development Center
  • Most Recent Events

    • 04 Jan 2016 Results published in the European Journal of Clinical Pharmacology
    • 09 Oct 2013 Status changed from recruiting to discontinued as reported by CliniclTrials.gov.
    • 28 Jan 2013 Planned End Date changed from 1 May 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top